Form 4: Kalaris CFO Gall Granted 235,000 Stock Options

Kalaris Therapeutics' Chief Financial Officer, Matthew Gall, was granted 235,000 stock options with an exercise price of $4.99, vesting over four years.

Summary

• Matthew Gall, Chief Financial Officer of Kalaris Therapeutics, Inc. (KLRS), was granted 235,000 stock options.
• The options have an exercise price of $4.99 per share.
• The grant date for these options was November 3, 2025.
• The options are scheduled to vest over four years, with 25% vesting on November 3, 2026, and the remainder vesting in equal monthly installments thereafter.
• Vesting is contingent upon continuous service.
• The options expire on November 2, 2035.
• Following this transaction, Matthew Gall directly beneficially owns 235,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed as a positive for corporate governance and long-term performance incentives, as it aligns management's interests with shareholders and serves as a retention mechanism. It does not, however, provide direct insight into operational or financial performance.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing performance.
• This type of equity compensation is a standard practice for executive retention and motivation.

Future Outlook

No specific forward-looking statements or guidance regarding company performance or financial results are provided in this transaction report.

Industry Context

The grant of stock options to a Chief Financial Officer is a common form of executive compensation across various industries, particularly in biotechnology and pharmaceutical sectors, to attract, retain, and motivate key talent by linking their compensation to company performance and shareholder value creation.

Comparison to Industry Standards

• Executive stock option grants are a standard component of compensation packages for senior management in publicly traded companies, comparable to practices at peers like Moderna (MRNA) or BioNTech (BNTX) where equity incentives are used to align executive and shareholder interests.
• The four-year vesting schedule with a one-year cliff (25% after one year) and monthly installments thereafter is a common structure designed to encourage long-term commitment and performance, similar to vesting schedules observed in many tech and biotech firms.

Corporate Governance

Related Party Transactions

• The grant of stock options to Matthew Gall, an officer of Kalaris Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a key management personnel.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with shareholder value creation.
• Employees: No direct impact on general employees, but reinforces the company's compensation strategy for key personnel.
• Management: Provides a significant long-term incentive for the Chief Financial Officer, enhancing retention and motivation.

Next Steps

• The stock options will vest according to the specified schedule, subject to Matthew Gall's continuous service with Kalaris Therapeutics.

Key Dates

Recommendation

This Form 4 reports a routine executive stock option grant, which is a standard compensation practice designed to align management's interests with shareholders. While positive for executive retention and motivation, it does not provide new fundamental information about the company's operations, financial health, or strategic direction to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Kalaris Therapeutics, KLRS, Matthew Gall, Stock Option, CFO, Executive Compensation, Equity Grant, Insider Transaction